[July 03, 2014]

EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against Regado Biosciences, Inc.

The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against Regado Biosciences, Inc. (NASDAQ:RGDO) resulting from allegations that the Company may have made false and misleading disclosures concerning its Phase 3 clinical trials.

On July 2, 2014 Regado Biosciences announced the suspension of its Phase 3 study of its anticoagulant drug, REG1 (now known as Revolixys Kit), pending a review of potential safety problems. In its announcement, Regado Biosciences stated: "that the Data Safety Monitoring Board, or DSMB, has initiated an unplanned review of data from the Company's Phase 3 trial of Revolixys Kit (previously known as REG1), entitled REGULATE-PCI (News - Alert), and that patient enrollment has been paused in the REGULATE-PCI tria until the DSMB has completed its analysis and communicated its recommendations." Regado Biosciences further explained that: "[t]he DSMB will conduct a full analysis of safety and treatment benefit-risk ratio of all patients enrolled to date (3234) with a focus on serious adverse events related to allergic reactions." Upon this news, shares of Regado Biosciences fell dramatically, damaging investors.

The Rosen Law Firm is preparing a class action lawsuit on behalf of Regado Biosciences investors. If you purchased Regado Biosciences securities prior to July 3, 2014, you may visit the website at http://rosenlegal.com to join the action. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

[ Back To TMCnet.com's Homepage ]